Mammoth Biosciences
Adam Garske has a diverse work experience in the field of biosciences. Adam currently holds the position of Associate Director of Protein Engineering at Mammoth Biosciences, starting in March 2023. Prior to this role, they served as a Principal Scientist I from March 2022 to April 2023, and as a Lead Scientist from November 2021 to March 2022, both at Mammoth Biosciences.
Before joining Mammoth Biosciences, Adam worked at International Flavors & Fragrances as a Senior Scientist from February 2021 to November 2021. Prior to that, they were employed at DuPont Industrial Biosciences (formerly Genencor) from September 2016 to February 2021, where they held the position of Senior Scientist. Adam also worked at the same company as a Scientist II from September 2011 to August 2016.
Adam's early career includes a position as an NIH-NRSA Postdoctoral Scholar at UCSF from September 2008 to August 2011. Adam also worked as a graduate student at the University of Wisconsin-Madison from July 2003 to August 2008.
Overall, Adam Garske has acquired extensive experience in the biosciences field, holding various roles in different organizations throughout their career.
Adam Garske earned a Ph.D. in Organic Chemistry from the University of Wisconsin-Madison, where they studied from 2003 to 2008. Prior to that, they obtained a Bachelor of Science (BS) degree in Chemistry from the University of St. Thomas, where they attended from 1999 to 2003. In addition, they hold a certification in Six Sigma Green Belt from DuPont.
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.